Psychocutaneous disease : Pharmacotherapy and psychotherapy - 18/04/17

Doi : 10.1016/j.jaad.2016.11.021

Helena Kuhn, MD ^a, Constance Mennella, DO ^b, Michelle Magid, MD ^c,^d,^e, Caroline Stamu-O’Brien, MD ^f, George Kroumpouzos, MD, PhD ^a,^g,^h,^⁎
^a Department of Dermatology, Alpert Medical School of Brown University, Providence, Rhode Island
^b Division of Child/Adolescent Psychiatry, Alpert Medical School of Brown University, Providence, Rhode Island
^c Department of Psychiatry at Dell Medical School, University of Texas at Austin, Austin, Texas
^d Department of Psychiatry, University of Texas Medical Branch at Galveston, Galveston, Texas
^e Department of Psychiatry, Texas A&M Health Science Center, Round Rock, Texas
^f Department of Psychiatry, New York University Medical School, New York, New York
^g Department of Dermatology, Medical School of Jundiaí, São Paulo, Brazil
^h GK Dermatology, PC, South Weymouth, Massachusetts

^∗Correspondence to: George Kroumpouzos, MD, PhD, Rhode Island Hospital, 593 Eddy Street, APC 10, Providence, RI 02903.Rhode Island Hospital593 Eddy Street, APC 10ProvidenceRI02903

Abstract

Building a strong therapeutic alliance with the patient is of utmost importance in the management of psychocutaneous disease. Optimal management of psychocutaneous disease includes both pharmacotherapy and psychotherapy. This article reviews psychotropic medications currently used for psychocutaneous disease, including antidepressants, antipsychotics, mood stabilizers, and anxiolytics, with a discussion of relevant dosing regimens and adverse effects. Pruritus management is addressed. In addition, basic and complex forms of psychotherapy, such as cognitive-behavioral therapy and habit-reversal training, are described.

Le texte complet de cet article est disponible en PDF.

Key words : antidepressant, antipsychotic, cognitive-behavioral therapy, drug, management, pruritus, psychocutaneous, psychotherapy

Abbreviations used : AED, CBT, EPS, FDA, HRT, OCRD, SSRI, TCA